IL6 and metabolic dysfunction-associated steatohepatitis: Analysis of upstream regulators predicted an increase in IL-6, which is frequently observed in MASH,44 and STAT3 that is inhibited by resmetirom,47 the only Food and Drug Administration-approved therapeutic for individuals with MASH48 (Figure 2G).